Simtuzumab

( DrugBank: Simtuzumab / KEGG DRUG: - )

2 diseases

ID	Disease name (Link within this page)	Number of trials
85	Idiopathic interstitial pneumonia	9

ID	Disease name (Link within this page)	Number of trials
94	Primary sclerosing cholangitis	2

85. Idiopathic interstitial pneumonia

Clinical trials : 627 / Drugs : 443 - (DrugBank : 120) / Drug target genes : 99 - Drug target pathways : 212

trials per page:

Showing 1 to 9 of 9 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2012-001571-36-PL (EUCTR)	09/09/2013	17/06/2013	A study to evaluate if a new drug is effective in preventing the progression of lung fibrosis	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy a ...	Idiopathic pulmonary fibrosis MedDRA version: 18.1;Level: PT;Classification code 10021240;Term: Idio ...	Product Code: GS-6624 INN or Proposed INN: Simtuzumab Other descriptive name: GS-6624	Gilead Sciences, Inc.	NULL	Not Recruiting			Female: yes Male: yes	500	Phase 2	United States;Czech Republic;Canada;Spain;Belgium;Poland;Australia;Israel;Germany;United Kingdom;Ita ...
2	EUCTR2012-001571-36-DE (EUCTR)	17/06/2013	02/04/2013	A study to evaluate if a new drug is effective in preventing the progression of lung fibrosis	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy a ...	Idiopathic pulmonary fibrosis MedDRA version: 18.0;Level: PT;Classification code 10021240;Term: Idio ...	Product Code: GS-6624 INN or Proposed INN: Simtuzumab Other descriptive name: GS-6624	Gilead Sciences, Inc.	NULL	Not Recruiting			Female: yes Male: yes	500	Phase 2	United States;Czech Republic;Canada;Poland;Spain;Belgium;Australia;Israel;Germany;United Kingdom;Ita ...
3	EUCTR2012-001571-36-BE (EUCTR)	28/05/2013	26/03/2013	A study to evaluate if a new drug is effective in preventing the progression of lung fibrosis	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy a ...	Idiopathic pulmonary fibrosis MedDRA version: 18.1;Level: PT;Classification code 10021240;Term: Idio ...	Product Code: GS-6624 INN or Proposed INN: Simtuzumab Other descriptive name: GS-6624	Gilead Sciences, Inc.	NULL	Not Recruiting			Female: yes Male: yes	500	Phase 2	Korea, Democratic People's Republic of;Israel;United Kingdom;Switzerland;Italy;France;Czech Republic ...
4	EUCTR2012-001571-36-ES (EUCTR)	12/05/2013	16/05/2013	A study to evaluate if a new drug is effective in preventing the progression of lung fibrosis	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy a ...	Idiopathic pulmonary fibrosis MedDRA version: 16.0;Level: PT;Classification code 10021240;Term: Idio ...	Product Code: GS-6624 INN or Proposed INN: Simtuzumab Other descriptive name: GS-6624	Gilead Sciences, Inc.	NULL	Not Recruiting			Female: yes Male: yes	500	Phase 2	United States;Czech Republic;Canada;Poland;Belgium;Spain;Australia;Israel;Germany;United Kingdom;Ita ...
5	EUCTR2012-001571-36-CZ (EUCTR)	29/04/2013	15/04/2013	A study to evaluate if a new drug is effective in preventing the progression of lung fibrosis	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy a ...	Idiopathic pulmonary fibrosis MedDRA version: 18.1;Level: PT;Classification code 10021240;Term: Idio ...	Product Code: GS-6624 INN or Proposed INN: Simtuzumab Other descriptive name: GS-6624	Gilead Sciences, Inc.	NULL	Not Recruiting			Female: yes Male: yes	500	Phase 2	United States;Czech Republic;Canada;Poland;Spain;Belgium;Australia;Israel;Germany;United Kingdom;Ita ...
6	EUCTR2012-001571-36-IT (EUCTR)	26/04/2013	28/02/2013	A study to evaluate if a new drug is effective in preventing the progression of lung fibrosis	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy a ...	Idiopathic pulmonary fibrosis MedDRA version: 14.1;Level: PT;Classification code 10021240;Term: Idio ...	Product Code: GS-6624 INN or Proposed INN: Simtuzumab Other descriptive name: GS-6624	Gilead Sciences, Inc.	NULL	Not Recruiting			Female: yes Male: yes	500	Phase 2	United States;Czech Republic;Canada;Poland;Spain;Belgium;Australia;Israel;Germany;United Kingdom;Ita ...
7	EUCTR2012-001571-36-GB (EUCTR)	19/04/2013	28/03/2013	A study to evaluate if a new drug is effective in preventing the progression of lung fibrosis	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy a ...	Idiopathic pulmonary fibrosis MedDRA version: 17.0;Level: PT;Classification code 10021240;Term: Idio ...	Product Code: GS-6624 INN or Proposed INN: Simtuzumab Other descriptive name: GS-6624	Gilead Sciences, Inc.	NULL	Not Recruiting			Female: yes Male: yes	500	Phase 2	United States;Czech Republic;Canada;Poland;Spain;Belgium;Australia;Israel;Germany;Italy;United Kingd ...
8	NCT01769196 (ClinicalTrials.gov)	January 31, 2013	14/1/2013	Study to Assess the Efficacy and Safety of Simtuzumab(GS-6624) in Adults With Idiopathic Pulmonary F ...	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy a ...	Idiopathic Pulmonary Fibrosis	Drug: Simtuzumab;Drug: Simtuzumab placebo	Gilead Sciences	NULL	Terminated	45 Years	85 Years	All	544	Phase 2	United States;Australia;Belgium;Canada;Czechia;France;Germany;Israel;Italy;Korea, Republic of;Poland ...
9	NCT01759511 (ClinicalTrials.gov)	October 18, 2012	15/11/2012	Long-Term Safety Study of GS-6624 in Adults With Idiopathic Pulmonary Fibrosis (IPF)	A Phase 2, Long-Term Safety Study of GS-6624 in Adult Subjects With Idiopathic Pulmonary Fibrosis (I ...	Idiopathic Pulmonary Fibrosis	Drug: Simtuzumab	Gilead Sciences	NULL	Terminated	18 Years	N/A	All	34	Phase 2	United States

First Previous1Next Last

94. Primary sclerosing cholangitis

Clinical trials : 148 / Drugs : 118 - (DrugBank : 39) / Drug target genes : 18 - Drug target pathways : 141

trials per page:

Showing 1 to 2 of 2 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2012-002473-61-IT (EUCTR)	18/06/2013	04/04/2013	A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety a ...	A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety a ...	Primary Sclerosing Cholangitis (PSC) MedDRA version: 14.1;Level: LLT;Classification code 10036732;Te ...	Product Name: Simtuzumab Product Code: GS-6624 INN or Proposed INN: Simtuzimab Product Name: Simtuzimab ...	Gilead Sciences Inc	NULL	Not Recruiting			Female: yes Male: yes	225	Phase 2	United States;Canada;Belgium;Spain;Denmark;Netherlands;Germany;United Kingdom;Italy;Sweden
2	NCT01672853 (ClinicalTrials.gov)	March 4, 2013	22/8/2012	Simtuzumab(GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults With Primary Sclero ...	A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety a ...	Primary Sclerosing Cholangitis (PSC)	Biological: Simtuzumab;Biological: Placebo	Gilead Sciences	NULL	Completed	18 Years	70 Years	All	235	Phase 2	United States;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom

First Previous1Next Last